Health Boards
Fri-02-01-2026, 20:33 PM
Very nice results, although the study shows that patients with an early response to vunakizumab tend to achieve better long-term outcomes, this association is likely driven by underlying treatment responsiveness rather than a causal effect of early improvement.
Of course, the post hoc design does not establish causality, nor does it exclude the possibility that patients without an early response may still achieve meaningful long-term benefit.
But it makes it possible for the doc, if he/she sees a quick response to tell the patient that she/he probably also will have a good long term effect.
Of course, the post hoc design does not establish causality, nor does it exclude the possibility that patients without an early response may still achieve meaningful long-term benefit.
But it makes it possible for the doc, if he/she sees a quick response to tell the patient that she/he probably also will have a good long term effect.
